Table 1.

MTT in experimental models of neurodegenerative and neurovascular disorders.

Neurological Diseases	Experimental Model	Species	Source of Mitochondria	Dose of Donor Mitochondria	Route of Administration
Alzheimer’s disease	Amyloid-β neurotoxicity Aged mice Olfactory bulbectomized mice with Alzheimer's type degeneration Cisplatin-induced cognitive deficits	WT (C57BL/6) BABL/c mice NMRI mice WT (C57BL/6)	HeLa cells Mouse liver Mouse brain Human MSCs	200 µg/mouse 5 mg/kg body weight 2 to 20 µg/mouse 170 µg/mouse	Intravenous injection [24] Intravenous injection [25] Intranasal delivery [182] Intranasal delivery [26]
Parkinson’s disease	6-OHDA MPTP 6-OHDA	Sprague-Dawley rats C57BL/6J Sprague–Dawley rats	PC12 cells and Human osteosarcoma HepG2 cells Rat livers	1.05 µg/rat 0.5 mg/kg body weight 200 µg/rat	Intracerebral injection [169] Intravenous injection [23] Intranasal delivery [27]
Stroke	Focal Ischemia Model MCAO MCAO MCAO MCAO	WT (C57BL/6) Wistar rats Sprague Dawley Rats Sprague Dawley Rats Sprague Dawley rats	Cryopreserved mouse placenta Human umbilical cord derived MSCs BHK-21 cells Pectoralis major Muscle N2a and mNSC cells	100 µg/mouse 10 µl/rat 75 µg/rat 5 × 106/10 µL 180-200 μg/rat	Intravenous injection [183] Intracerebral injection [184] Intracerebral injection [185] Intracerebral injection [29] Intraarterial injection [186]